FrancophonIA/ELRC3.0 huggingface dataset:
English: Section 4.1 - Therapeutics indications in adults - capsules and tablets
Estonian: Lõik 4.1 Täiskasvanute näidustused (kapslid ja tabletid)
English: a) “Treatment of symptomatic gastro-oesophageal reflux disease (GERD)” The MAH proposed that both duodenal and gastric ulcers be presented in individual indications separate from the GERD indication.
Estonian: a) „Sümptomaatilise gastroösofageaalse reflukshaiguse ravi” Müügiloa hoidja tegi ettepaneku, et gastroösofageaalse reflukshaiguse ravi näidustuse kõrval oleks eraldi välja toodud ka kaksteistsõrmiksoole haavandi ja maohaavandi ravi näidustused.
English: The cardinal symptoms associated with GERD are heartburn and regurgitation.
Estonian: Gastroösofageaalse reflukshaiguse peamised sümptomid on kõrvetised ja maomahla regurgitatsioon.
English: Identified or suspected adverse drug reactions are listed in this sections.
Estonian: Selles lõigus on esitatud omeprasooli kasutamisel täheldatud või kahtlustatavate kõrvalnähtude loetelu.
English: The CHMP noted that study data showed that 20 mg once daily produces a more pronounced and consistent inhibition than the lower doses and therefore agreed on a maximum daily dose of 20 mg. Selftreatment should be limited to a maximum period of 14 days, and the patient should be instructed to consult a doctor if symptoms persist.
Estonian: Inimravimite komitee märkis, et uuringuandmetel tekitas omeprasooli 20 mg ööpäevane annus suurema ja püsivama happetekke vähenemise kui väiksemad annused, mistõttu suurima soovitatava ööpäevase annusena lepiti kokku 20 mg.
English: In most patients healing occurs within four weeks.
Estonian: Enamikul patsientidest paraneb haavand neljanädalase raviga.
English: Regarding the prevention of non-steroidal anti-inflammatory drug (NSAID) -associated gastric ulcers, duodenal ulcers or gastroduodenal erosions in patients at risk, prevention of ulcer formation in at risk NSAID users is a reasonable course of action, given the high and increasing incidence.
Estonian: Mittesteroidseid põletikuvastaseid ravimeid NSAID-ravimid) kasutavate riskirühma patsientide puhul on mõistlik ravistrateegia NSAID-ravimite kasutamisest tingitud maohaavandite, kaksteistsõrmiksoole haavandite või gastroduodenaalsete erosioonide tekke ennetamine, arvestades nende haigusseisundite üha suurenevat esinemissagedust.
English: The indication and the associated posology were removed from the harmonised SPC.
Estonian: Seetõttu jäeti näidustus ja asjaomane annustamisteave ravimi omaduste kokkuvõtte ühtlustatud versioonist välja.
English: For the treatment of symptomatic gastro-oesophageal reflux disease, the recommended dose is 20 mg daily.
Estonian: Sümptomaatilise gastroösofageaalse reflukshaiguse ravis on soovitatav annus 20 mg ööpäevas.
English: For children and adolescents over 4 years of age treated for duodenal ulcers caused by H. pylori, the selection of the appropriate combination therapy should take into consideration the official national, regional and local guidance regarding bacterial resistance, duration of treatment and appropriate use of antibacterial agents.
Estonian: Üle 4-aastastel lastel ja noorukitel, kellel ravitakse H. pylori põhjustatud kaksteistsõrmiksoole haavandit, tuleb sobiva kombinatsioonravi valikul arvestada riiklike,
English: • Long-term management of patients with healed reflux esophagitis
Estonian: • Pikaajaline säilitusravi pärast refluksösofagiidi paranemist
English: The CHMP considered that the prevention of NSAID ulcers is sufficiently demonstrated and considered these indications to be approvable.
Estonian: Inimravimite komitee leidis, et NSAID-ravimite kasutamisest tingitud haavandite ennetamine on piisaval määral tõendatud, ja pidas kõnealuste näidustuste heakskiitmist põhjendatuks.
English: The CHMP considered that there is sufficient information on human experience to state that excretion of omeprazole in milk is low and unlikely to influence the child. Data from epidemiological studies on use of Losec during pregnancy indicates no adverse effects and the CHMP considered that omeprazole can be used during pregnancy.
Estonian: Andmed epidemioloogilistest uuringutest Loseci kasutamise kohta raseduse ajal ei näita kõrvalnähte, mistõttu inimravimite komitee leidis, et omeprasooli võib kasutada raseduse ajal.
English: The CHMP considered that prevention of relapse of H. pylori negative duodenal ulcers is sufficiently demonstrated and considered these indications to be approvable.
Estonian: Inimravimite komitee leidis, et H. pylori-negatiivsete kaksteistsõrmiksoole haavandite relapsi ennetamine on piisaval määral tõendatud, ja otsustas, et näidustused on põhjendatud.
English: • Symptomatic treatment of heartburn and acid regurgitation in gastro-esophageal reflux disease In children and adolescents over 4 years of age
Estonian: • Kõrvetiste ja happe regurgitatsiooni sümptomaatiline ravi gastroösofageaalse reflukshaiguse korral
English: • Treatment of NSAID-associated gastric and duodenal ulcers
Estonian: • NSAID-ravimite kasutamisest tingitud maohaavandi ja kaksteistsõrmiksoole haavandi ravi
English: The scope of the referral included all licences, whether prescription only (POM/Rx) or non-prescription (over-thecounter or OTC).
Estonian: Esildis hõlmas kõiki ravimi müügilube, sõltumata sellest, kas tegu oli retsepti- või käsimüügiravimiga.
English: The CHMP considered that the prevention of relapse of H. pylori negative gastric ulcers is sufficiently demonstrated and considered these indications to be approvable.
Estonian: Inimravimite komitee leidis, et H. pylorinegatiivsete maohaavandite relapsi ennetamine on piisaval määral tõendatud, ja otsustas, et näidustused on põhjendatud.
English: In patients with poorly responsive duodenal ulcer 40 mg once daily is recommended and healing is usually achieved within four weeks.
Estonian: Ravile halvasti reageeriva kaksteistsõrmiksoole haavandiga patsientidel soovitatakse kasutada annust 40 mg üks kord ööpäevas, mille korral paraneb haavand tavaliselt neljanädalase raviga.
English: In patients with poorly responsive gastric ulcer 40 mg once daily is recommended and healing is usually achieved within eight weeks.
Estonian: Ravile halvasti reageeriva maohaavandiga patsientidel soovitatakse annust 40 mg üks kord ööpäevas, mille korral paraneb haavand tavaliselt kaheksanädalase raviga.
English: d) “Treatment of gastric ulcers” and “Prevention of relapse of gastric ulcers” The gastric ulcer indications were separated from the duodenal ulcer indications as well as from the NSAID-related and H. pylori positive ulcers.
Estonian: d) „Maohaavandi ravi” ja „Maohaavandi relapsi ennetamine” Maohaavandi ravi näidustus eraldati kaksteistsõrmiksoole haavandi, mittesteroidsete põletikuvastaste ravimite (NSAID-ravimid) kasutamisest tingitud haavandi ja H. pylori-positiivse haavandi ravi näidustustest.
English: For long-term management of patients with healed reflux oesophagitis, the recommended dose is 10 mg once daily.
Estonian: Soovitatav annus pikaajaliseks säilitusraviks patsientidel, kellel söögitorupõletik on paranenud, on 10 mg üks kord ööpäevas.
English: • Prevention of relapse of duodenal ulcers
Estonian: • Kaksteistsõrmiksoole haavandi relapsi ennetamine
English: Section 4.1 - Therapeutics indications in paediatric patients - capsules and tablets
Estonian: Lõik 4.1 Laste näidustused (kapslid ja tabletid)
English: Paediatric posology: capsule and tablet
Estonian: Annustamine lastel (kapslid ja tabletid)
English: • Treatment of reflux esophagitis
Estonian: • Refluksösofagiidi ravi
English: For the treatment of NSAID-associated gastric and duodenal ulcers, the recommended dose is 20 mg once daily.
Estonian: NSAID-ravimite kasutamisest tingitud maohaavandite ja kaksteistsõrmiksoole haavandite ravis on soovitatav annus 20 mg üks kord ööpäevas.
English: These are based on established data and are currently confirmed as the most efficacious combinations, and are intended to allow treatment alternatives according to local needs and clinical practice.
Estonian: See raviviis põhineb usaldusväärsetel andmetel ja seda peetakse kõige efektiivsemaks teadaolevaks kombinatsiooniks.
English: For prevention of relapse in patients with poorly responsive gastric ulcer the recommended dose is 20 mg once daily.
Estonian: Soovitatav annus maohaavandi relapsi ennetamiseks või ravile halvasti reageeriva maohaavandiga patsientidel on 20 mg üks kord ööpäevas.
English: In patients with severe oesophagitis 40 mg once daily is recommended and healing is usually achieved within eight weeks.
Estonian: Raske ösofagiidiga patsientidel soovitatakse kasutada annust 40 mg üks kord ööpäevas, mille korral söögitorupõletik paraneb tavaliselt kaheksanädalase raviga.
English: • In combination with antibiotics in treatment of duodenal ulcer caused by H. pylori
Estonian: • H. pylori põhjustatud kaksteistsõrmiksoole haavandi ravi koos antibiootikumidega”
English: Section 4.7: Effects on ability to drive and use machines - all formulations
Estonian: Lõik 4.7 Toime reaktsioonikiirusele (kõik ravimvormid)
English: g) Acid-related dyspepsia
Estonian: g) „Ülihappesusest tingitud düspepsia”
English: The SPC therefore states that co-administration of atazanavir and nelfinavir with proton pump inhibitors is not recommended and that if co-administration is judged unavoidable, close clinical monitoring is recommended together with an increase of the anti-retroviral drug dose, as plasma levels of nelfinavir and atazanavir are decreased in case of co-administration with omeprazole.
Estonian: Kui samaaegne kasutamine on hädavajalik, on soovitatav jälgida hoolikalt kliinilist seisundit ja suurendada retroviiruseravimi annust, sest nelfinaviiri ja atasanaviiri plasmakontsentratsioonid vähenevad samaaegse omeprasooliravi korral.
English: The CHMP agreed that the available data on administration of the MUPS tablet immediately after a high-fat breakfast shows delayed and decreased absorption of omeprazole.
Estonian: Inimravimite komitee nõustus samuti, et kättesaadavate andmete kohaselt imendub omeprasool hiljem ja vähem, kui MUPS
English: In general, the SPC and the PL of the OTC Losec presentation was aligned to that of the Prescription-only products.
Estonian: Üldjoontes ühtlustati Loseci käsimüügis turustatava ravimi omaduste kokkuvõte ja pakendi infoleht retseptiravimite omadega.
English: In particular, the indications and their associated posology recommendations were harmonised.
Estonian: Eelkõige ühtlustati näidustuste ja annustamise lõike.
English: • Prevention of relapse of gastric ulcers
Estonian: • Maohaavandi relapsi ennetamine
English: Symptoms responding adequately to an acid suppressant and returning upon discontinuation allow a diagnosis of GERD.
Estonian: Gastroösofageaalse reflukshaiguse diagnoosile viitavad mao happesust vähendavale ravile hästi alluvad, ent ravi lõpetamisel taastuvad sümptomid.
English: Nelfinavir coadministration is contraindicated, atazanavir co-administration is not recommended.
Estonian: Omeprasooli samaaegne manustamine koos nelfinaviiriga on vastunäidustatud, samas kui samaaegne manustamine atasanaviiriga ei ole soovitatav.
English: For the treatment of reflux oesophagitis, the recommended dose is 20 mg once daily.
Estonian: Maohaavandi ravis on soovitatav annus 20 mg üks kord ööpäevas.
English: For the treatment of duodenal ulcers, the recommended dose is 20 mg once daily.
Estonian: Kaksteistsõrmiksoole haavandi ravis on soovitatav annus 20 mg üks kord ööpäevas.
English: For the treatment of gastric ulcers, the recommended dose is 20 mg once daily.
Estonian: Refluksösofagiidi ravis on soovitatav annus 20 mg üks kord ööpäevas.
English: It is in the so-called “idiopathic ulcers” that the prevention of relapse of H. pylori negative duodenal and gastric ulcer indications are indicated.
Estonian: H. pylori-negatiivse kaksteistsõrmiksoole haavandi ja maohaavandi relapsi ennetamine on eelkõige näidustatud nn idiopaatiliste haavandite korral.
English: Reflux oesophagitis results from the combination of excessive gastro-oesophageal reflux of gastric juice and impaired oesophageal clearance of the refluxate.
Estonian: b) „Refluksösofagiidi ravi” ja „Pikaajaline säilitusravi pärast refluksösofagiidi paranemist” Refluksösofagiidi tekkepõhjus on ühelt poolt maohappe liigne gastroösofageaalne refluks ja teiselt poolt tagasivoolanud maohappe ebapiisav kliirens söögitorus.
English: A response is usually seen in two to four weeks.
Estonian: Ravivastus ilmneb tavaliselt kahe kuni nelja nädala jooksul.
English: The full EPAR and risk management plan summary for Duloxetine Zentiva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Duloxetine Zentiva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: • pain due to diabetic peripheral neuropathy (damage to the nerves in the feet, legs, hands and arms that can occur in patients with diabetes);
Estonian: • valu, mida põhjustab diabeetiline perifeerne neuropaatia (jalgade ja käte närvikahjustus, mida võib esineda diabeediga patsientidel);
English: A risk management plan has been developed to ensure that Duloxetine Zentiva is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Duloxetine Zentiva võimalikult ohutu kasutamine.
English: Since these neurotransmitters are involved in maintaining mood and reducing the sensation of pain, blocking their re-uptake into nerve cells can improve the symptoms of depression, anxiety and neuropathic pain.
Estonian: Et kõnealused neurotransmitterid osalevad hea meeleolu säilitamises ja valutunde vähendamises, võib nende närvirakkudesse tagasihaarde pärssimine leevendada depressiooni, ärevuse ja neuropaatilise valu sümptomeid.
English: The Committee recommended that Duloxetine Zentiva be approved for use in the EU.
Estonian: Komitee soovitas Duloxetine Zentiva kasutamise Euroopa Liidus heaks kiita.
English: Duloxetine Zentiva is available as gastroresistant capsules (30 and 60 mg).
Estonian: Duloxetine Zentivat turustatakse gastroresistentsete kapslitena (30 ja 60 mg).
English: What measures are being taken to ensure the safe and effective use of Duloxetine Zentiva?
Estonian: Mis meetmed võetakse, et tagada Duloxetine Zentiva ohutu ja efektiivne kasutamine?
English: Duloxetine Zentiva is used to treat adults with the following diseases:
Estonian: Duloxetine Zentivat kasutatakse järgmiste haiguste raviks täiskasvanutel:
English: In patients who respond to Duloxetine Zentiva, treatment should continue for several months, to prevent the disorder coming back.
Estonian: Patsiendid, kellel tekib Duloxetine Zentivale ravivastus, peavad jätkama ravimi võtmist mitu kuud, et ennetada haiguse taastumist.
English: For major depression, the recommended dose of Duloxetine Zentiva is 60 mg once a day.
Estonian: Raske depressiooni raviks on Duloxetine Zentiva soovitatav annus 60 mg üks kord ööpäevas.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Duloxetine Zentiva has been shown to have comparable quality to Cymbalta and to be bioequivalent to Cymbalta.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Duloxetine Zentiva võrreldav kvaliteet ja bioekvivalentsus ravimiga Cymbalta.
English: For diabetic neuropathic pain, the recommended dose is 60 mg per day but some patients may need a higher dose of up to 120 mg per day.
Estonian: Diabeetilise neuropaatilise valu raviks on soovitatav annus 60 mg üks kord ööpäevas, kuid mõnel patsiendil võib olla vaja suuremat annust kuni 120 mg ööpäevas.
English: In patients who respond to Duloxetine Zentiva, treatment should continue for several months to prevent the disease coming back, or for longer in patients who have had repeated periods of depression in the past.
Estonian: Zentivale ravivastus, peavad jätkama ravimi võtmist mitu kuud, et ennetada haiguse taastumist; samuti peavad ravimi võtmist jätkama patsiendid, kellel on varem olnud korduvaid depressiooniepisoode.
English: Other information about Duloxetine Zentiva
Estonian: Muu teave Duloxetine Zentiva kohta
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Duloxetine Zentiva, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Duloxetine Zentiva omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: This is a summary of the European public assessment report (EPAR) for Duloxetine Zentiva.
Estonian: See on ravimi Duloxetine Zentiva Euroopa avaliku hindamisaruande kokkuvõte.
English: By blocking their re-uptake, duloxetine increases the amount of these neurotransmitters in the spaces between nerve cells, increasing the level of communication between the cells.
Estonian: Neurotransmitterite tagasihaarde pärssimise kaudu suurendab duloksetiin nende arvu närvirakkude vahel, suurendades rakkudevahelist signaalivahetust.
English: What is Duloxetine Zentiva and what is it used for?
Estonian: Mis on Duloxetine Zentiva ja milleks seda kasutatakse?
English: The active substance in this medicine, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor.
Estonian: Duloxetine Zentiva toimeaine duloksetiin on serotoniini ja noradrenaliini tagasihaarde inhibiitor.
English: For practical information about using Duloxetine Zentiva, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Duloxetine Zentiva kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: This means that Duloxetine Zentiva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Cymbalta.
Estonian: See tähendab, et Duloxetine Zentiva on sarnane võrdlusravimiga Cymbalta, millel juba on Euroopa Liidus müügiluba.
English: Duloxetine Zentiva contains the active substance duloxetine and is is a ‘generic medicine'.
Estonian: Duloxetine Zentiva sisaldab toimeainena duloksetiini ja on geneeriline ravim.
English: For more information about treatment with Duloxetine Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Duloxetine Zentivaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Because Duloxetine Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Duloxetine Zentiva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The dose of Duloxetine Zentiva should be reduced gradually when stopping treatment.
Estonian: Ravi katkestamisel tuleb Duloxetine Zentiva annust vähendada järk-järgult.
English: Because Duloxetine Zentiva is a generic medicine of Cymbalta, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Duloxetine Zentiva on Cymbalta geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: It is not intended to provide practical advice on how to use Duloxetine Zentiva.
Estonian: Hindamisaruandes ei anta Duloxetine Zentiva kasutamise praktilisi nõuandeid.
English: Therefore, the CHMP's view was that, as for Cymbalta, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Cymbalta korral, ületab ravimi Duloxetine Zentiva kasulikkus sellega kaasnevad riskid.
English: Why is Duloxetine Zentiva approved?
Estonian: Miks Duloxetine Zentiva heaks kiideti?
English: Duloxetine Zentiva duloxetine
Estonian: Duloxetine Zentiva duloksetiin
English: How has Duloxetine Zentiva been studied?
Estonian: Kuidas Duloxetine Zentivat uuriti?
English: How is Duloxetine Zentiva used?
Estonian: Kuidas Duloxetine Zentivat kasutatakse?
English: How does Duloxetine Zentiva work?
Estonian: Kuidas Duloxetine Zentiva toimib?
English: What are the benefits and risks of Duloxetine Zentiva?
Estonian: Milles seisneb Duloxetine Zentiva kasulikkus ja mis riskid ravimiga kaasnevad?
English: Oncaspar received a marketing authorisation valid throughout the EU on 14 January 2016.
Estonian: Oncaspar on saanud müügiloa, mis kehtib kogu Euroopa Liidus, 14. jaanuaril 2016.
English: Further information on Oncaspar can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR Oncaspar.
Estonian: Lisateave Oncaspari kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR Oncaspar.
English: Oncaspar (pegaspargase)
Estonian: Oncaspar (pegaspargaas)
English: The healthcare professional should give the medicine in a hospital where resuscitation equipment is available.
Estonian: Meditsiinitöötaja peab ravimit manustama haiglas, kus on olemas elustamisvahendid.
English: What measures are being taken to ensure the safe and effective use of Oncaspar?
Estonian: Mis meetmeid võetakse, et tagada Oncaspari ohutu ja efektiivne kasutamine?
English: However, the data in adult patients were limited and the company that markets the medicine is to provide further data of its benefit in this group of patients.
Estonian: Täiskasvanud patsientide andmed olid siiski piiratud ja ravimit turustaja esitab täiendavad andmed ravimi kasulikkuse kohta selles patsiendirühmas.
English: Other information about Oncaspar
Estonian: Muu teave Oncaspari kohta
English: The European Medicines Agency therefore decided that Oncaspar's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Oncaspari kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Oncaspar is used in combination with other cancer medicines.
Estonian: Oncaspari kasutatakse koos teiste vähiravimitega.
English: As for all medicines, data on the use of Oncaspar are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Oncaspari kasutamise kohta pidevat järelevalvet.
English: As for its risks, the side effects of Oncaspar are similar to those of other asparaginase medicines and are considered manageable
Estonian: Riskide osas sarnanevad Oncaspari kõrvalnähud muude asparaginaasi sisaldavate ravimite kõrvalnähtudega ja neid peetakse hallatavateks.
English: What is Oncaspar and what is it used for?
Estonian: Mis on Oncaspar ja milleks seda kasutatakse?
English: The company that markets Oncaspar will complete two more studies on the safety and effectiveness of Oncaspar, which will help further clarify the benefits and risks of this medicine in adults and in newly diagnosed patients.
Estonian: Oncasparit turustaja lõpetab kaks täiendavat uuringut Oncaspari ohutuse ja efektiivsuse kohta, mis aitavad täiendavalt selgitada ravimi kasulikkust ja riske täiskasvanutel ning esmadiagnoosiga patsientidel.
English: For more information about using Oncaspar, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Oncaspari kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Side effects reported with Oncaspar are carefully evaluated and any necessary action taken to protect patients.
Estonian: Oncaspari kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: The most common side effects with Oncaspar (which may affect more than 1 in 10 people) include signs of liver problems (raised levels of liver enzymes and bilirubin in the blood), reduced blood clotting, high levels of fats in the blood, high levels of blood glucose and low levels of white blood cells accompanied by fever.
Estonian: Oncaspari kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on maksaprobleemide nähud (maksaensüümide suurenenud sisaldus veres), vere vähenenud hüübimine, vere suur rasvasisaldus, vere suur glükoosisisaldus ja leukotsüütide (vere valgeliblede) vähesus koos palavikuga.